Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809405 | PMC |
| http://dx.doi.org/10.3399/bjgp13X674378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
Curr Oncol Rep
June 2024
The Meet-URO Group, Italian Network for Research in Uro-Oncology, Milan, Italy.
Purpose Of Review: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care.
Recent Findings: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges.
Multi-institutional evaluation of a Pareto navigation guided automated radiotherapy planning solution for prostate cancer.
Radiat Oncol
April 2024
Radiotherapy Physics Department, Velindre Cancer Centre, CF14 2TL, Cardiff, Wales, UK.
Background: Current automated planning solutions are calibrated using trial and error or machine learning on historical datasets. Neither method allows for the intuitive exploration of differing trade-off options during calibration, which may aid in ensuring automated solutions align with clinical preference. Pareto navigation provides this functionality and offers a potential calibration alternative.
View Article and Find Full Text PDFTiming of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).
Ann Oncol
July 2024
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London. Electronic address:
Background: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for prostate-specific antigen (PSA) failure.
Patients And Methods: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, preoperative PSA≥10 ng/ml) for recurrence after radical prostatectomy.
Article Synopsis
- Platelet activation is linked to the spread of cancer, and ongoing trials are testing if aspirin can help prevent this process by reducing platelet activation.
- A study involving 716 cancer patients measured a specific biomarker (U-TXM) related to platelet activation after treatment and its relation to patient factors and aspirin use.
- Results showed that while lower doses of aspirin significantly reduced U-TXM levels across different cancer types, higher doses didn’t provide any additional benefit; elevated U-TXM levels suggest ongoing malignancy activity, especially in patients with colorectal and gastro-oesophageal cancers.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
June 2022
MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.
Background: STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden disease. In this final analysis, we report long-term findings on the primary outcome measure of OS and on the secondary outcome measures of symptomatic local events, RT toxicity events, and quality of life (QoL).
Methods And Findings: Patients were randomised at secondary care sites in the United Kingdom and Switzerland between January 2013 and September 2016, with 1:1 stratified allocation: 1,029 to standard of care (SOC) and 1,032 to SOC+RT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!